VRCA
Verrica Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.45
−4.30%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.50
- Revenue estimate
- $6.4M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.62
- EPS estimate
- -$0.39
- Revenue actual
- $5.9M
- Revenue estimate
- $5.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +28.1%
- Revenue beats (12Q)
- 8
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.39 | -$0.62 | Miss -60.00% | $5.9M |
| May 12, 2026 | -$0.59 | -$0.41 | Beat 30.51% | $5.0M |
| Mar 11, 2026 | -$0.73 | -$0.51 | Beat 30.33% | $5.1M |
| Nov 14, 2025 | -$1.14 | $0.13 | Beat 111.40% | $14.3M |
| Aug 12, 2025 | -$0.70 | $0.02 | Beat 102.86% | $12.7M |
| Mar 11, 2025 | -$0.25 | -$0.24 | Beat 4.00% | $344.0K |
| Aug 14, 2024 | -$0.43 | -$0.31 | Beat 27.91% | $5.2M |
| Feb 29, 2024 | -$0.47 | -$0.48 | Miss -2.13% | $2.0M |
| Nov 9, 2023 | -$0.22 | -$0.32 | Miss -45.45% | $2.9M |
| Mar 6, 2023 | -$0.20 | -$0.11 | Beat 45.00% | $68.0K |
| Aug 11, 2022 | -$0.32 | -$0.32 | In line | $214.0K |
| Mar 2, 2022 | -$0.48 | -$0.35 | Beat 27.08% | -$12.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026